A 67-year-old man with thrombocytopenia, and amegakaryocytic but otherwise normal bone marrow, was evaluated. Antibody against thrombocytes was negative and the half-life of thrombocytes was normal. In vitro clonal culture of the patient's bone marrowcells yielded no megakaryocyte colony with normal granulocyte-macrophage and erythroid colony formation.
Introduction
Acquired amegakaryocytic thrombocytopenic purpura (AATP) is characterized by thrombocytopenia, markedly decreased or completeabsence of bonemarrowmegakaryocytes and minimal changes in other hematopoietic cell lines (1-3). The clinical course is highly variable and no standard treatment is available (1-3). It may precede overt leukemia (1, 2, 4) and other hematologic diseases (1, 2, 4, 5) in some patients. On the other hand, the disease state may remain unchanged for as long as 15 years (6). Bleeding tendency is often serious and patients with fatal bleeding have been reported (7). Werecently encountered a patient with AATPwith humoral inhibitory factor(s) for megakaryocyte colony formation ( 1 , 8) . Therapeutic trials with plasma exchange (2), cyclosporine (4, 9, 10), prednisoione (2-4), and cyclosporine plus prednisoione (9) were all ineffective in this patient.
Case Report
A 67-year-old man was referred to the Shinshu University Hospital for the evaluation and treatment of thrombocytopenia which was first noticed at the age of 62, but had been left untreated as there were no symptomsrelated to the thrombocytopenia. The family history and the patient' s past history were unremarkable.
Physical examination revealed many petechiae and small ecchymoses on the extremities and abdominal wall and a few bleeding spots on the retinae. Hepatosplenomegaly was absent and physical findings were otherwise normal. Hematuria and occult blood of the stool were negative, however superficial bleeding was found in the stomach by an endoscopic examination. The platelet count was 8x109/l; the blood count was otherwise normal. Bonemarrowexamination showedan absence of megakaryocytes with the erythroblastic and granulopoietic series normally present. A bone marrow cytogenetic study showed a 46XY normal karyotype. The Coombs' test, the antinuclear antibody, and the platelet-associated IgG were negative, as well as serological tests for toxoplasma, brucella, syphilis, human immunodeficiency virus, Epstein-Barr virus, and hepatitis B and C viruses. Fibrinogen and partial thromboplastin time, and folic acid were normal and serum vitamin B12 level was 2,830 pg/ml (normal range 200) . There was mild liver dysfunction possibly due to excessive drinking in the past but the blood chemistry was otherwise normal. Adrenal and thyroid functions were normal. A neoplastic process elsewhere was ruled out by appropriate tests.
The half-life of the platelet was normal (1 1) (t1/2, 7.34 days, performed on July 23, 1991). An in vitro methylcellulose culture of the patient's bone marrowmononuclear cells (12) yielded no megakaryocyte colony in the presence of 100 U/ml recombinant human interleukin 3 (IL-3), 1 0 ng/ml recombinant humangranulocyte -macrophage colony-stimulating factor (GM-CSF), 2 U/ml recombinant human erythropoietin (Epo) and 80 mg/ml recombinant human IL-6 (performed on July 15, 199 1).
On the other hand, other colonies including granulocytemacrophage, eosinophil and mixed hemopoietic colonies, and erythroid bursts colonies were formed normally. Addition of the patient's serum to the culture of the control bone marrow nonphagocytic mononuclear cells (NPMNC) derived from a patient with essential thrombocytosis resulted in significant suppression of megakaryocyte colony formation: 20.7±3.3/ 2xlO4 NPMNCvs 41.3+ll.9/2xlO4 NPMNC, with patient's sera and control sera, respectively (p<0.05, n=3 for each condition, performed on July 30, 1991).
Clinical course and results of therapeutic trials (Fig. 1) On July 13, 1991, platelet concentrates (8 packs) were transfused for the first time. The platelet count was >13xl09/l with no treatment for the next 7 months. On March 2, 1992, the platelet count decreased to 8xl09/l and the second platelet transfusion was performed. Because the patient was asymptomatic except for petechiae on the skin, platelets were infused only when the platelet count decreased to fewer than 8xl09/l. The platelet-associated IgG was weakly positive on April 7, 1 992; we considered the appearance of platelet-associated IgG as due to the repeated platelet transfusions. However, the disappearance rate of transfused platelets remained constant (t2/i, 2.6-5.4 days) before and after the appearance of the IgG, indicating that excessive destruction of the platelets did not take place.
Plasma exchange ( 1 ,500 ml each time) was performed three times on March 18, 26 and 27, 1992, but the platelet count did not increase significantly. From April 15, 1992, 5 mg/kgBW/ day (BW53 kg) p.o. cyclosporine was started. During the next 75 days, the platelet count was more than 10xl09/l suggesting some beneficial effect from the drug. Side effects ofcyclosporine such as liver and kidney dysfunction, leukocytopenia and gingival hypertrophy were not observed. However, on July 3, 1992, the platelet count decreased to 9x 109/L Cyclosporine was discontinued because the therapeutic effect of the drug was eventually judged to be absent, and 50 mg/day prednisolone was startedp.o. on July 14, 1992. The prednisolone therapy was not clearly effective and frequent platelet transfusion was needed. Finally, 20 mg/day prednisolone plus 5 mg/kgBW/day cyclosporine was administered from August 26, 1992 to October 12, 1992, however, the combination therapy did not significantly raise the platelet count. Thereafter, the patient has been receiving a small amount of prednisolone (3.75-10 mg/day) alone, with the platelet count being 9-22x109/l and no serious bleeding episodes.
Discussion
AATPis a rare hematologic disorder characterized by the isolated absence of bone marrowmegakaryocytesand consequent thrombocytopenia ( 1 -3). According to a literature search, there has been only one case reported of the disease in Japan ( 1 3 , 14). Its etiology is not well understood and seemingly diverse; alcoholic abuse, abnormality in the megakaryocytesor its progenitors themselves, and suppression of the megakaryocytes or its progenitors by autoimmune mechanism have been listed sive agents were unsuccessful in the majority of the patients (1 , 2), however, favorable effects from prednisolone (2, 3, 5, 6) and/or cyclosporine (9) were reported in some cases. In the previous literature, the youngest and eldest patients were 15 (1, 2) and 83 (5) years of age, respectively, and the age at the development of the disease does not appear to be important. The platelet count in this disorder reportedly ranged from 2.5-70xl09A (1, 2, 5), and was highly variable. Thus, the age and the degree of thrombocytopenia in the present case were within the reported range. There is a high likelihood that the present patient possessed somehumoralfactor(s) against megakaryocyte colony formation. Although we did not purify the humoral factor(s), it might have been IgG as described by Hoffman (7). Such factor(s) were present in 13% (2 of 15) of the patients in whomthe presence of it was searched for in the previous literature. In a patient reported by Nagasawaand colleagues (14), in vitro suppression of colony-forming unitmegakaryocytes by the patient's T cells was found.
Wedid not perform such a cytotoxicity assay in the present case.
Regarding treatment, plasma exchange (2), immune suppression with steroids (2, 3, 5, 6), cyclosporine (9) and other drugs , and anti-thymocyte immunoglobulin (9) have been tried in patients with AATP,and possible beneficial effects have been reported in a small number of patients (4, 9). More specifically, Hoffman (7) proposed prednisone, plasmapheresis , cyclophosphamide and/or cyclosporine for patients with AATP due to abnormal IgG production and antithymocyte globulin, and cyclosporine and/or cytokine therapy for those with T-cell mediated suppression of thrombocyte formation. However, Manoharenand colleagues concluded that treatment of any kind appeared to be ineffective (4). Unfortunately, this was also the case in the present patient. Wetried all of the previously reported treatments except for antithymocyte immunoglobulin and found none of them to be effective. Spontaneous fluctuation in the platelet count has been reported in AATP (15), and we believe the data shown in Fig. 1 exhibits such a fluctuation rather than a change due to treatment. Thrombocytopenia was first incidentally discovered at the age of62 in the presentpatient and, until now, the clinical course was benign without serious bleeding episodes. However, careful follow-up of the condition is required due to the frequent transition of AATPto leukemia and other moremalignant conditions (1, 2, 9).
